TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19290751

Group type: EXPERIMENTAL
Intervention: Active interventions
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral strategies
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Information and emotional support
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Environmental modifications
Number of subjects: 224
Study: 17241408

Group type: EXPERIMENTAL
Intervention: 64 U of BoNTA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14614579

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11299066

Group type: EXPERIMENTAL
Intervention: Continuous lateral rotation (CLR) with specialized bed
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CLR with P&PD
Number of subjects: 19

Group type: COMPARATOR
Intervention: Routine turning every 2 h
Number of subjects: 19

Group type: COMPARATOR
Intervention: Routine turning every 2 h with P&PD
Number of subjects: 19
Study: 9397236

Group type: EXPERIMENTAL
Intervention: Randomized controlled trial (RCT) with 10 to 40 mg fosinopril daily
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Open label trials with 10 to 40 mg fosinopril daily
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: All four study designs (RCT and open trials)
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Unstructured open trial of 10 to 40 mg fosinopril daily
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Unstructured open trial
Number of subjects: 2964
Study: 7966514

Group type: EXPERIMENTAL
Intervention: 1500 pulses at 12.5 KV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2000 pulses at 12.5 KV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2500 pulses at 12.5 KV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3000 pulses at 12.5 KV
Number of subjects: 40
Study: 3308719

Group type: EXPERIMENTAL
Intervention: imidazole salicylate (750 mg t.i.d. per os)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ibuprofen (600 mg t.i.d. per os)
Number of subjects: 60
Study: 31845326

Group type: EXPERIMENTAL
Intervention: Effort self-talk ("I will do my very best!")
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ability self-talk ("I am very good at this!")
Number of subjects: 212

Group type: COMPARATOR
Intervention: No self-talk
Number of subjects: 212
Study: 29402521

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 2.5 mg PO once weekly for 26 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 5 mg PO once weekly for 26 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 10 mg PO once weekly for 26 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg SC every other week plus blinded MTX 20 mg PO once weekly for 26 weeks
Number of subjects: 395
Study: 27221805

Group type: EXPERIMENTAL
Intervention: 200 mg of fragmented Lactobacillus amylovorus CP1563 daily for 12 weeks
Number of subjects: 200
Study: 25603130

Group type: EXPERIMENTAL
Intervention: Temporally unpredictable shocks with varying levels of cue unpredictability
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined cue and temporal unpredictability
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined cue and temporal predictability
Number of subjects: 72

Group type: COMPARATOR
Intervention: Temporally predictable shocks
Number of subjects: 72
Study: 23101451

Group type: EXPERIMENTAL
Intervention: Surgical group (STA-MCA bypass)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Medical group (best medical therapy)
Number of subjects: 195
Study: 20038612

Group type: EXPERIMENTAL
Intervention: 5FC-CR formulation 1 (1,500 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5FC-CR formulation 2 (1,500 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Immediate-release 5FC product (Ancobon)
Number of subjects: 5
Study: 19159590

Group type: COMPARATOR
Intervention: KIR2DL1 gene phenotype frequency in UC patients (0.710)
Number of subjects: 279

Group type: COMPARATOR
Intervention: KIR2DL3 gene phenotype frequency in UC patients (0.620)
Number of subjects: 279

Group type: COMPARATOR
Intervention: KIR2DL1 gene phenotype frequency in CD patients (0.740)
Number of subjects: 279

Group type: COMPARATOR
Intervention: KIR2DL1 HLA-C2 combination in UC patients (0.380)
Number of subjects: 279

Group type: COMPARATOR
Intervention: KIR2DL1 HLA-C2 combination in CD patients (0.411)
Number of subjects: 279
Study: 16432469

Group type: EXPERIMENTAL
Intervention: Thick, low water content, soft contact lens fitted under a light patch to one eye of diabetic patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Thick, low water content, soft contact lens fitted under a light patch to one eye of nondiabetic control subjects
Number of subjects: 46
Study: 14983417

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KHQ (King's Health Questionnaire)
Number of subjects: 0
Study: 11771603

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask (ILM)
Number of subjects: 55
Study: 9685963

Group type: EXPERIMENTAL
Intervention: 10 micrograms Heberbiovac-HB vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5 micrograms Heberbiovac-HB vaccine
Number of subjects: 2
Study: 8314499

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 million units (MU) subcutaneously thrice weekly for four months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b
Number of subjects: 58
Study: 2876497

Group type: EXPERIMENTAL
Intervention: Somatostatin octapeptide (SMS 201-995)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Somatostatin (native hormone)
Number of subjects: 13
Study: 28816023

Group type: EXPERIMENTAL
Intervention: Community sensitization sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-sensitization survey
Number of subjects: 0
Study: 26146964

Group type: EXPERIMENTAL
Intervention: Self-identified goals using the Canadian Occupational Performance Measure (COPM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Moderate UE functional capacity
Number of subjects: 65

Group type: COMPARATOR
Intervention: Age and UE hand dominance
Number of subjects: 65
Study: 24993561

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep hygiene education
Number of subjects: 0
Study: 22525048

Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.001% twice daily (n = 47)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.005% twice daily (n = 48)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.005% once daily (n = 44)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Cyclosporine 0.05% twice daily (n = 47)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Vehicle (n = 47)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 327

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.005% once daily
Number of subjects: 327
Study: 19056135

Group type: EXPERIMENTAL
Intervention: G‐CSF treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: G‐CSF group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: After withdrawal of G‐CSF
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Plasma concentration of SDF-1 at stent implantation
Number of subjects: 59
Study: 17719848

Group type: EXPERIMENTAL
Intervention: Hypoxia-altitude (n=9)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normoxia-altitude (n=6)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normoxia-sea level (n=7)
Number of subjects: 22
Study: 16339790

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group P‐4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group P‐6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (P‐4 and P‐6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation with unbound propofol concentration
Number of subjects: 30
Study: 14651992

Group type: EXPERIMENTAL
Intervention: Endurance-trained subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both trained and sedentary subjects
Number of subjects: 0
Study: 10826412

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg/day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study: 8877027

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) 200 u kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 1499473

Group type: EXPERIMENTAL
Intervention: 0.2 U/kg body wt NPH insulin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.5 g/day metformin
Number of subjects: 16

Group type: COMPARATOR
Intervention: glyburide alone
Number of subjects: 16
Study: 6209324

Group type: EXPERIMENTAL
Intervention: Pollen extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buffer
Number of subjects: 0
Study: 30080730

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (LAP)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Open resection (OPEN)
Number of subjects: 462
Study: 29537981

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemia
Number of subjects: 1439

Group type: COMPARATOR
Intervention: Standard glycemic management
Number of subjects: 1439
Study: 25887817

Group type: EXPERIMENTAL
Intervention: Blade Plate (BPL)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Screw-side Plate (SSP)
Number of subjects: 734
Study: 24667134

Group type: EXPERIMENTAL
Intervention: Polyphenol antioxidant (PA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 12
Study: 21901262

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser microscopy (CLM)
Number of subjects: 21
Study: 20973744

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (lutein 3.2 mg, L-glutathione 5 mg, vitamin E 15 IU, vitamin C 150 mg, zinc 40 mg, copper 2 mg, selenium 40 mcg, manganese 5 mg) administered once a day for 3 months.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls (no antioxidant supplementation).
Number of subjects: 15
Study: 17381555

Group type: EXPERIMENTAL
Intervention: Headache patients (n=70)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: RAP patients (n=70)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Controls (n=70)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Migraineurs (subgroup of headache patients)
Number of subjects: 210
Study: 15694064

Group type: COMPARATOR
Intervention: Computerised referral guidelines for GPs
Number of subjects: 289

Group type: COMPARATOR
Intervention: Nurse counsellor intervention
Number of subjects: 289
Study: 12059890

Group type: EXPERIMENTAL
Intervention: Inguinal field block (IFB) with ropivacaine (50-60 ml, 5 mg/ml) before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia with wound infiltration postoperatively
Number of subjects: 60
Study: 10204872

Group type: EXPERIMENTAL
Intervention: Space flight (17 day Spacelab mission)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (7 subjects)
Number of subjects: 4
Study: 7779538

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (AOT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conditioning therapy
Number of subjects: 20
Study: 2277155

Group type: EXPERIMENTAL
Intervention: XR‐Ionomer (Kerr)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: XR‐Ionomer with polyacrylic acid (PAA) pretreatment (Kerr)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitrabond (3M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketac‐Bond (ESPE‐Premier)
Number of subjects: 40
Study: 6446052

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 200
Study: 30741803

Group type: EXPERIMENTAL
Intervention: Elective induction of labor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 28917363

Group type: EXPERIMENTAL
Intervention: Music intervention (Buddhist music for 30 minutes before sleep)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Music video intervention (Buddhist music videos for 30 minutes before sleep)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study: 26914986

Group type: EXPERIMENTAL
Intervention: SRP + 10% E. officinalis gel application
Number of subjects: 46

Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 46
Study: 24097277

Group type: EXPERIMENTAL
Intervention: Simultaneous transurethral PVBT/PVP
Number of subjects: 62

Group type: COMPARATOR
Intervention: PVBT alone
Number of subjects: 62
Study: 21769657

Group type: EXPERIMENTAL
Intervention: Mutually violent group (n=81)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Victims-only group (n=39)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Non-violent group (n=367)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Perpetrator-only group (n=32)
Number of subjects: 519
Study: 19545427

Group type: EXPERIMENTAL
Intervention: 5 POUNDS gift voucher (incentive group)
Number of subjects: 2144

Group type: COMPARATOR
Intervention: No gift voucher (no incentive group)
Number of subjects: 2144
Study: 17514666

Group type: EXPERIMENTAL
Intervention: Ultrasonographic AAA screening
Number of subjects: 6040

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 6040
Study: 15743276

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n=906)
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care (n=895)
Number of subjects: 1801
Study: 12085257

Group type: EXPERIMENTAL
Intervention: HPV 16 seropositive individuals
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HPV 18 seropositive individuals
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HPV 16 seropositive individuals above age 45
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HPV 16 seropositive individuals with lag time < 10 years
Number of subjects: 28
Study: 9616313

Group type: COMPARATOR
Intervention: R093877 1 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: R093877 2 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 17
Study: 8129159

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 2508213

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enprostil 7 micrograms twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin 500 mg four times a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31769106

Group type: EXPERIMENTAL
Intervention: Bony nasopharynx depth
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pharyngeal tonsil depth
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adenoid-nasopharyngeal ratio (ANR)
Number of subjects: 200
Study: 30103299

Group type: EXPERIMENTAL
Intervention: Deep heating therapy (DHT) via MF diathermy (450 KHz)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Superficial heating therapy (SHT) via electric resistance
Number of subjects: 49
Study: 28338369

Group type: EXPERIMENTAL
Intervention: DHA-rich tuna fish oil (560mg DHA / 140mg EPA, 2 × 1g/day for 8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (soy oil, 2 × 1g/day for 8 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: DHA-rich tuna fish oil
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study: 26379095

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery system
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 58
Study: 22905853

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 3254

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 3254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3254

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg and 20 mg
Number of subjects: 3254
Study: 21807638

Group type: EXPERIMENTAL
Intervention: Endopredict (EP) risk score
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: Combination of Adjuvant!Online, quantitative ER, Ki67, and treatment with EP
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: EPclin risk score
Number of subjects: 1702
Study: 18799004

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (maintaining glucose levels between 80 and 110 mg/dl)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Standard insulin therapy (maintaining glucose levels between 180 and 200 mg/dl)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 504

Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 504
Study: 16779924

Group type: EXPERIMENTAL
Intervention: Intramuscular injections (IG) - 5 x 2 mL over 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral tablets (OG) - one tablet daily for 30 days
Number of subjects: 0
Study: 14579880

Group type: EXPERIMENTAL
Intervention: Premier MicroDose Porcelain Bonding/Optibond FL adhesive/Prodigy composite
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Premier MicroDose Porcelain Bonding/PQ1 adhesive/Amelogen composite
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultradent Porcelain Etch/Optibond FL adhesive/Prodigy composite
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultradent Porcelain Etch/PQ1 adhesive/Amelogen composite
Number of subjects: 40
Study: 11434574

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 9600821

Group type: COMPARATOR
Intervention: Standard external beam pelvic irradiation (RT) 5000 cGy in 25 fractions
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: RT with infusional IV 5‐FU 1g/m2 daily in the first and last 4 days of RT
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Partially hyperfractionated RT, 5280 cGy in 33 fractions, two fractions per day on the first and last 4 days of RT
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Partially hyperfractionated RT with concurrent 5‐FU
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Standard RT and 5‐FU in stratum 1 (IB/IIA or medial parametrial IIB disease)
Number of subjects: 234
Study: 7908693

Group type: EXPERIMENTAL
Intervention: Formula supplemented with soy oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula supplemented with soy and marine oils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial ready-to-feed liquid formula (control)
Number of subjects: 0
Study: 3048235

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 mg/kg bodyweight) given 20 min prior to infusion of intravenous immunoglobulin.
Number of subjects: 10

Group type: COMPARATOR
Intervention: No methylprednisolone prophylaxis given.
Number of subjects: 10
Study: 31460865

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with financial incentives (shopping vouchers) for cannabis abstinence over 12 once-weekly sessions, confirmed using urinalysis. Maximum value of vouchers: £240.
Number of subjects: 551

Group type: COMPARATOR
Intervention: Control arm receiving treatment as usual only.
Number of subjects: 551
Study: 28545506

Group type: EXPERIMENTAL
Intervention: Web-based intervention for 10 weeks (subjective self-monitoring)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Web-based intervention for 10 weeks with Fitbit Zips (objective self-monitoring)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 100
Study: 25668262

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (10 g/d)
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study: 24107587

Group type: COMPARATOR
Intervention: DASH diet score quartiles
Number of subjects: 3215

Group type: COMPARATOR
Intervention: Mediterranean diet score quartiles
Number of subjects: 3215
Study: 21590466

Group type: EXPERIMENTAL
Intervention: Stented group (n = 144)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Nonstented group (n = 142)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Both groups (stented and nonstented)
Number of subjects: 505
Study: 18082163

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 16571429

Group type: EXPERIMENTAL
Intervention: Ongoing training group (trained again to proficiency at 1 and 3 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 18
Study: 12724020

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10931081

Group type: EXPERIMENTAL
Intervention: 2 IU/d sc human recombinant growth hormone for a mean of 14 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9294798

Group type: EXPERIMENTAL
Intervention: 95-degree DCS plate with dispersed screw configuration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Genucephalic intramedullary nail with grouped screw configuration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Genucephalic intramedullary nail
Number of subjects: 12

Group type: COMPARATOR
Intervention: 95-degree DCS plate
Number of subjects: 12
Study: 30212555

Group type: EXPERIMENTAL
Intervention: Alternative package leaflets (drug facts box with/without reading instruction, narrative format with numbers)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard package leaflet
Number of subjects: 397